RETEVMO, approved by the FDA on May 8, 2020, is indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as well as adults and children 12 years and older with either advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate). Crossing the blood-brain barrier, this drug shrinks tumors in parts of the central nervous system, including the brain. This is important to RET fusion-positive NSCLC patients because up to 50% can have tumors that metastasize to the brain.
“This is a critical new treatment option for patients with RET-driven lung and thyroid cancers because RETEVMO inhibits RET,” said Brandon Tom, vice president of commercial services with Biologics. “We’re proud to be able to work with Eli Lilly to help make this therapy available for patients to take at home.”
Biologics specialty pharmacy is committed to and recognized for its quality level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply-skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.
Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.